Metabolomics Services Market Size

As per Market Research Future Analysis, the Global Metabolomics Services Market was valued at USD 2.94 Billion in 2024 and is projected to reach USD 7.41 Billion by 2035, growing at a CAGR of 12.26% from 2025 to 2035. The market is driven by the increasing prevalence of cancer, technological advancements in instrumentation, and the expanding applications of metabolomics in various fields such as toxicology, environmental analysis, and disease research. The COVID-19 pandemic has further highlighted the importance of metabolomics in understanding disease mechanisms and developing effective treatments. Key players in the market include Agilent Technologies, Waters, and Thermo Fisher Scientific, among others.

<p>Agilent Technologies, Inc. (U.S.), Waters (U.S.), Bruker (U.S.), TMIC (Canada), Thermo Fisher Scientific (U.S.), Biocrates Life Sciences AG (Austria), Creative Proteomics (U.S.), Human Metabolome Technologies America Inc (Japan), Shimadzu Corporation (Japan), Metabolon, Inc. (U.S.)</p>

Jan 2021 OWL and BIOSFER, biotech players, have arrived at a strategic partnership to reinforce R&D in developing diagnostic methods and personalized medicine use metabolomics. The agreement permits both groups to identify prospects, produce detailed proposals, and find the most suitable backing to safeguard these projects' victory and make them advantageous for society and the biotechnology industry. OWL and BIOSFER have widespread knowledge of metabolomic technology for application in various areas, such as increasing new biomarkers to create diagnostic products or encourage advanced platforms for studies and clinical tests in the pharmaceutical industry. 

Jan 2021 numares A.G., a leading metabolomics diagnostics company, and Bruker Corporation have decided to cooperate to bring novel diagnostics tests employing NMR to the laboratory market unmet medical requirements. The tests are created on the automated measurement of metabolites via artificial intelligence and a strong magnetic field. The platform is advertised under the numares brand AXINON. This partnership will support the current transition of AXINON  platform from research into routine clinical use and makes it accessible to all patients as a reasonably priced, day-to-day diagnostic standard.

Aug 2020 Metabolon, Inc., the global leader in metabolomics, has entered into a multi-year association with Merck KGaA, Germany, a top science and technology company. Merck KGaA, Germany, runs its biopharmaceuticals business in the U.S. and Canada as EMD Serono. Metabolon will back clinical & translational research developments through therapeutic areas as an exploratory metabolomics associate. Through this partnership, Metabolon will achieve worldwide metabolomics and deliver top biological interpretation and examination of the results to shed light on biomarkers and biochemical pathways detected to progress both the rapidity and yield of Merck KGaA's drug development pipeline.

July 2020 ReviveMed has announced that they are pursuing an assessment analysis with Bristol Myers Squibb. This analysis will use ReviveMed's artificial intelligence (A.I.) platform to understand the mechanisms of resistance and response to immunotherapies in cancer patients. ReviveMed has built one of the most comprehensive databanks about metabolites and their relation with other molecules. Their exclusive A.I. algorithm utilizes this database to classify a large number of metabolites for individual patients quickly and at a low cost. ReviveMed's AI-driven platform interprets this large number of data to discover novel disease mechanisms and molecules for drug discovery purposes.